Vancouver, Canada, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the successful convening of its inaugural Annual Scientific Advisory Board (SAB) meeting. This meeting brought together eight world-renowned professors and experts in psychiatry, addiction research, a ...